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Abstract. The objective of the present work was to study the effects of erythrocyte proteins phosphorylation in erythrocyte
aggregation and deformability. Human whole blood samples were incubated in vitro in absent and in presence of the phos-
phorylation/dephosphorilation band 3 inhibitors and also with adenylyl cyclase, guanylate cyclase and PI3K inhibitors and the
erythrocyte aggregation index (EAI) and deformability were assayed. The results show that when band 3 is phosphorylated in
presence of a PTP inhibitor an increase in erythrocyte aggregation index is observed (p < 0.0001). A partial dephosphorylation
band 3 state, induced by PTK inhibitors, show a decrease in the erythrocyte aggregation index (p < 0.002). However both
manipulated states induced lower EAI values than blood samples aliquots controls. The guanylate cyclase and PI3-K inhibitors
significantly decrease the erythrocyte aggregation index in relation with the control blood samples. Erythrocyte deformability
in presence of all the inhibitors did not showed significant changes. PTP and PI3-K inhibitors showed a significantly increase
in the plasma potassium concentrations not associated with EAI values. Methehemoglobin levels were increased significantly
when guanylate cyclase inhibitor is present in the blood samples. In conclusion, the results suggest that erythrocyte aggregation
index is dependent of the phosphorylated/dephosphorylated state of band 3.
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1. Introduction
The red blood cells (RBCs) tendency to aggregate is destabilised by the blood flow and also by the
repulsive forces coming from the outer membrane molecule charges [1,2,17,25,37]. The erythrocytes are
brought together forming “rouleaux” that are mediate by plasma proteins among which the fibrinogen
molecule receives the major preponderance [36].
An increase in the fibrinogen is observed in those pathologies associated with inflammatory condi-
tions such as cardiovascular diseases [1,19,24,25], being the fibrinogen considered as a cardiovascular
risk factor [4,5,14,18]. For example in hypertension and in atherosclerosis the increase in erythrocyte
aggregation could be attributed to an increase in plasma fibrinogen concentration [10,30,41,42].
There are several in vitro studies where maintaining constant plasma fibrinogen concentration the
red blood cells aggregation tendency changes in presence of effectors namely β-estradiol, buflomedil,
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epinephrine, ethanol, flunarizine, acetylcholine, spermineNONOate, calcium and choline [3,4,11,12,26,
31–33,39,45].
Erythrocyte hyper aggregation and deformability impairment could together increase blood viscosity
either hindering blood flow in large vessels or occluding it in the microvessels [16,18,28,34,35].
Several approaches could be made to understand the RBCs aggregation changes both in vivo and
in vitro. For example we have observed that applying fluorescence methodology β-estradiol binds to
fibrinogen with changes in the protein conformational states [38]. These results could tell us that some
fibrinogen molecules were not in the optimal conditions to bridge RBCs, favouring the decrease of
erythrocyte aggregation as has been verified [11].
Looking inside the erythrocyte there are evidences that cytoskeleton protein phosphorylation mod-
ify the membrane stability [40] and that tyrosine phosphorylation of protein band 3 inhibits glycolytic
enzymes binding [29] but facilitate the efflux of nitric oxide [44].
Nitric oxide synthase inhibitors and guanylate cyclase inhibition reduced erythrocyte deformability,
suggesting that NO is a determinant of RBC mechanical behaviour [22].
It was observed by us that adding acetylcholine to erythrocyte suspensions the nitric oxide (NO) mo-
bilization and the levels of nitrites and nitrates are increase [6]. We have raised the hypothesis that the
phosphorylation/dephosphorylation of band 3 could be responsible for the signal transduction mecha-
nism induced by acetylcholine [6], which could explain the RBC hemorheological parameters behaviour
previously obtained [33].
In this sense the aim of this work was to verify if the modulation of the phosphorylation degree of
band 3 influence the human erythrocyte hemorheological properties. In particular, the in vitro effects of
band 3 inhibitors of phosphorylation/ dephosphorylation and adenylyl cyclase, guanylate cyclase and
PI3K inhibitors were evaluated.
2. Material and methods
2.1. Materials
General reagents were provided by Sigma-Aldrich Co. For protein tyrosine kinase (PTK) inhibition
Syk, a PTK p72syk inhibitor (Calbiochem, Merck, Darmstadt, Germany), Aminogenistein (AMGT),
a PTK p53/56lyn inhibitor (Calbiochem, Merck, Darmstadt, Germany) and DMPQ (Calbiochem, Merck,
Darmstadt, Germany), a potent and selective inhibitor of human vascular beta-type platelet derived
growth factor receptor tyrosine kinase were used. Calpeptin (Calp) a calpain inhibitor, from Calbiochem,
Merck, Darmstadt, Germany was used for PTP inhibition. Guanylate cyclase inhibition was achieved
with Ly-83583 (Ly) also from Calbiochem, Merck, Darmstadt, Germany. Wortmannin (Wort), a PI3-K
inhibitor and MDL hydrochloride (MDL) an adenylyl cyclase inhibitor were purchased from Sigma-
Aldrich Co. Inhibitors were prepared as recommended in the information sheet of the products: Wort,
AMGT, Ly, Syk and Calp were prepared in a DMSO solution at 10−3 M concentration; DMPQ and
MDL were prepared in distilled water at the same concentration.
2.2. Blood sampling and incubation procedure
Blood was supplied, according protocol, by the Portuguese Institute of Blood, Lisbon. Blood samples
were collected into tubes with lithium heparin (17 IU/ml) as anticoagulant. Total blood was divided
into two aliquots of 1 ml each and centrifuged at 11 000 rcf (Biofuge 15 centrifuge, Heraeus) during 1
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minute at room temperature. Then 10 μl of plasma were replaced by the same volume of either phys-
iological serum or inhibitor, so that the final concentration of the inhibitor in the whole plasma was
10−5 M. Besides other concentrations (5 × 10−5, 10−6 and 5 × 10−6 M) were tested, no significant
alterations were observed with these concentrations in relation to 10−5 M. Then the blood sample was
homogenised by gently inversion and erythrocytes aggregation and incubated for 15 minutes, then de-
formability, pH, oxygen tension at half saturation of blood (p50), ions (sodium, potassium and calcium),
hemoglobin (Hb), oxyhemoglobin (O2Hb), methemoglobin (MetHb) and hydrogen carbonate (HCO−3 )
concentrations were determined.
2.3. Erythrocyte aggregation index
Erythrocyte aggregation was determined using the MA1 aggregometer from Myrenne GMBH (Roet-
gen, Germany). The MA1 aggregometer consists of a rotating cone plate chamber, which disperses the
sample by high shear rate of 600 s−1, and a photometer that determines the extent of aggregation. The
intensity of light, exerted by a light emitting diode is measured after transmission through the blood sam-
ple. The aggregation was determined in stasis for 10 seconds, after dispersion of the blood sample [25].
2.4. Erythrocyte deformability
The erythrocyte deformability for different shear stress (0.30, 0.60, 1.20, 3.00, 12.00, 30.00 and
60.00 Pa) was determined by using the Rheodyn SSD shear stress diffractometer from Myrenne GMBH
(Roentgen, Germany) and erythrocyte deformability is expressed as the elongation index (EI) in per-
centage. The Rheodyn SSD diffractometer determines RBC deformability by simulating the shear forces
exerted by the blood flow and vascular walls on the erythrocytes [8]. Erythrocytes are suspended in a
viscous medium and placed between a rotating optical disk and a stationary disk. A well-defined shear
force is exerted upon the suspension which forces the erythrocytes to deform to ellipsoids and align with
the fluid shear stresses. If a laser beam is allowed to pass through the erythrocyte suspension a diffraction
pattern appears on the opposite end. That diffraction pattern will be circular with resting erythrocytes,
but becomes elliptical when the erythrocytes are deformed by shear. The light intensity of the diffraction
pattern are measured at two different points (A and B), equidistant from the center of the image. The
erythrocyte elongation index (EEI), in percentage, is obtained according the following formula:
EEI(%) = A−B
A + B
× 100.
2.5. K+, Na+, Ca2+ and HCO−3 plasma concentrations, pH, p50, Hb, O2Hb and MetHb
determinations
After the additions of the inhibitors Hb, O2Hb and MetHb were determined with the Osm3 hemoxime-
ter from Radiometer. pH, p50, K+, Na+, Ca2+ and HCO−3 concentrations in blood were determined with
the ABL505 Blood Gas-Electrolyte System from Radiometer (Copenhagen, Demark).
2.6. Statistical methods
Data are presented as means± SD. The differences between the mean values were evaluated by using
Student’s t test for paired samples. A p value less than 0.05 was considered statistically significant.
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3. Results
3.1. Effects on erythrocyte aggregation and deformability
The EAI values changes significantly when blood samples were incubated with phosphorylation and
dephosphorylation inhibitors in relation to the control value of 15.94 ± 3.6 (nd). Comparing an almost
dephosphorylation state of band 3 (AMGT and DMPQ) with a totally phosphorylated state (Calp) there
is a significant difference in EAI (p < 0.04). However both manipulated in vitro phosphorylated and
desphosphorylated states induce lower EAI values when compared with the control aliquot (Fig. 1).
The presence of the guanylate cyclase inhibitor (Ly) and PI3-K inhibitor (Wort) in the incubated
aliquots, decrease significantly the EAI, p < 0.0002 and p < 0.001, respectively, when compared with
the control. Adenylyl cyclase inhibitor (MDL) did not significantly change erythrocyte aggregation in
relation to the control aliquot (Fig. 2).
Figures 3 and 4 showed that the values of erythrocytes elongation indexes measured at different shear
stresses did not significantly change with the presence of any of the used inhibitors in the blood samples
aliquots when comparing with the control aliquot.
3.2. Effects on sodium, potassium, calcium and hydrogen carbonate concentrations
In all blood samples aliquots there were no significant variations on the plasma calcium, sodium
or hydrogen carbonate concentrations in presence of any of the inhibitors used in the study (Table 1)
when compared with the control aliquot. Highly increased values were obtained in presence of the PTP
inhibitor (Calp) (p < 0.0001) and also in the presence of the PI3-K inhibitor (Wort) (p < 0.004) for
K+ plasma concentration in relation to the control aliquot no other statistical differences were obtained
when the remainder inhibitors were added to blood samples aliquots in relation to the control one (Figs 5
and 6). Comparing those potassium concentrations values with the EAI values obtained we did not
obtained significant correlation between the two parameters, meaning that the aggregation alterations
are not plasma K+ concentration dependent (Fig. 7).
Fig. 1. Erythrocyte aggregation values (mean± SD) obtained in vitro with protein tyrosine-kinases inhibitors (Syk, AMGT and
DMPQ) and a phosphotyrosine-phosphatase inhibitor (Calp). There are significant decreases in the aggregation indexes with
all the used inhibitors although a significant difference (p < 0.04) is observed between the totally phosphorylated (Calp) and
the partially desphosphorylated (Syk, AMGT and DMPQ) state.
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Fig. 2. Erythrocyte aggregation (mean ± SD) values after incubation with soluble guanylate cyclase inhibitor (Ly), PI3-K
inhibitor (Wort) and adenylyl cyclase inhibitor (MDL).
Fig. 3. Erythrocyte elongation index (EEI) with protein tyrosine-kinases inhibitors (Syk, AMGT and DMPQ) and phospotyro-
sine-phosphatase inhibitor (Calp). There were no significant differences on EEI.
3.3. Effects on pH, Hb, oxyHb and MetHb concentrations
Table 1 show that no significant differences are observed in pH, Hb and oxyHb concentrations values
after the addition of the inhibitors to the blood samples aliquots. Methehemoglobin levels are, comparing
with the control aliquot (1.5 ± 0.2%), increased (3.0 ± 0.5%) in the presence of a guanylate cyclase
inhibitor (Ly).
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Fig. 4. Erythrocyte elongation index (EEI) obtained in vitro with guanylate cyclase inhibitor (Ly), PI3-K inhibitor (Wort) and
adenylyl cyclase inhibitor (MDL). There were no significant differences on EEI.
Table 1
Values (mean ± SD) of whole blood concentrations of Na+, Ca2+ and HCO−3 , pH, and hemoglobin, oxyhemoglobin and
methemoglobin concentrations after in vitro incubations with the studied inhibitors
C Syk AMGT DMPQ
[Na+] (mmol/l) 139.4± 1.7 141.0± 2.3 142.1± 2.1 137.9± 1.5
[Ca2+] (mmol/l) 1.0± 0.2 1.1± 0.2 1.1± 0.2 1.0± 0.2
[HCO−3 ] (mmol/l) 25.5± 1.7 25.8± 1.2 25.18± 1.2 24.8± 1.1
pH 7.4± 0.03 7.4± 0.04 7.4± 0.02 7.4± 0.02
Hb (g/dL) 15.2± 1.5 15.2± 0.9 15.1± 1.3 15.6± 1.4
O2Hb (%) 70.0± 11.2 67.3± 12.3 72.13± 11.1 72.18± 10.9
MetHb (%) 1.5± 0.2 1.6± 0.1 1.6± 0.1 1.5± 0.1
p50 (mmHg) 24.8± 1.9 26.0± 1.7 26.4± 1.6 23.0± 7.7
Calp Ly Wort MDL
[Na+] (mmol/l) 142.0± 2.4 141.5± 1.8 142.7± 2.3 138.7± 1.5
[Ca2+] (mmol/l) 1.0± 0.2 1.1± 0.2 1.0± 0.2 1.0± 0.2
[HCO−3 ] (mmol/l) 24.9± 2.9 25.7± 1.2 25.6± 1.8 23.4± 3.8
pH 7.4± 0.03 7.4± 0.03 7.4± 0.03 7.4± 0.02
Hb (g/dl) 15.4± 1.2 15.2± 1.1 15.1± 1.2 15.3± 1.0
O2Hb (%) 65.5± 15.2 65.2± 12.5 67.3± 11.6 65.6± 17.9
MetHb (%) 1.5± 0.1 3.0± 0.5* 1.5± 0.1 1.5± 0.1
p50 (mmHg) 26.5± 1.7 25.8± 1.9 26.5± 1.7 26.0± 1.9
Syk, AMGT and DMPQ – PTK inhibitors; Calp – PTP inhibitor; Ly – Guanylate cyclase inhibitor; MDL – adenylyl cyclase
inhibitor. Wort – PI3K inhibitor.
*p < 0.0001.
C. Saldanha et al. / Modulation of erythrocyte hemorheological properties 189
Fig. 5. Values (mean ± SD) of K+ concentrations obtained in vitro with protein tyrosine-kinases inhibitors (Syk, AMGT and
DMPQ) and phosphotyrosine-phosphatase inhibitor (Calp). There was a significant increase in the K+ concentration with the
PTK inhibitors Syk and AMGT, p < 0.001 and p < 0.0007, respectively. A highest increase is observed with the PTP inhibitor
(Calp) p < 0.0001.
Fig. 6. Values (mean±SD) of K+ concentrations obtained in vitro with guanylate cyclase inhibitor (Ly), PI3-K inhibitor (Wort)
and adenylyl cyclase inhibitor (MDL). PI3-K inhibitor significantly increases K+ levels, p < 0.004.
4. Discussion
It is described that a post-translational modifications exist in the cytoplasmic domain of band 3 (cdb3)
in the tyrosine residues under phosphorylation and dephosphorylation by PTKs (protein tyrosine kinase)
and PTPs (protein-phosphotyrosine phosphatases) respectively [21,27]. In mature erythrocytes tyrosine
kinases Syk (p72 syk) and Lyn (p56/53 lyn) a member of the c-src kinases family are responsible for
phosphorylation states and a certain dynamic balance exist between these state and a dephosphoryla-
tion one mediated by PTB1B [2,20]. When cdb3 is phosphorylated the glycolytic enzymes (aldolase,
phosphofrutokinase 1, glyceraldehyde-3-phosphate dehydrogenase) actually binding dissociated to the
cytoplasm [29]. At variance when cdb3 is dephosphorylated those glycolytic enzymes are bound with a
concomitant impairment of the lactic fermentation [15,43].
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Fig. 7. Correlation between the erythrocyte aggregation indexes (EAI) and the potassium concentration in presence of the PI3-K
inhibitor.
In this study was verified that the alteration on red blood cell protein band 3 phosphorylation and
dephosphorylation states mediated by the PTK and PTP inhibitors induce a significantly decreased in
erythrocyte aggregation and less unmodified erythrocyte deformability of venous blood samples col-
lected from healthy humans (Figs 1–4). However the EAI values obtained in presence of Syk inhibitor
are significantly lower than in presence of the PTP inhibitor (Fig. 1).
When calpeptin (PTP1B inhibitor) is added to the blood samples aliquots the band 3 became phospho-
rylated and an over stimulation of the lactic fermentation will be expected with the adenosine triphos-
phate produced (ATP) deviated by PTKs as its co-substrate. If it happens probably less amount of ATP
is disposal to the physiological transport action of the Na+/K+-ATPase activity and in consequence an
unbalance in the RBC ionic gradients could be expected. In fact, an increased in the plasma K+ ions
concentrations was observed in the blood samples aliquots in the presence of calpeptin (Fig. 5) which is
in accordance with the above raised hypothesis, without any concentration dependence (Fig. 7).
However when the Syk and the Lyn inhibitors are added to the blood samples aliquots the cdb3 stays
in a less phosphorylated state which comprise a great glycolytic enzyme affinity to the protein band 3,
may be followed by a decrease in the lactic fermentation rate and an increase in the oxidative part
of the pentose phosphate pathway as observed by [13]. Besides a reduced ATP concentration is ex-
pected, in relation to normal conditions, the remaining will be utilised in the active transport proteins
Na+/K+-ATPase and Ca2+-ATPase because no changes are observed in these ions plasma concentra-
tions. These results could indicate that the observed values of erythrocyte aggregation are not dependent
of the intracellular calcium concentration which has been described early by Cicco et al. as an activator
of erythrocyte aggregation [9].
Considering our “in vitro model” for the study of the two states of protein band 3 a less phosphorylate
and a more phosphorylate one and maintaining fibrinogen concentration constant, changes in the EAI are
obtained with a significantly increase when cdb3 is more phosphorylated than it is dephosphorylated.
This behaviour when compared with the control aliquot shows that both states decreases erythrocyte
aggregation which seems not to be an ion concentration based dependent mechanism as discussed above.
The signal transduction mechanism responsible for the EAI changes is under study.
The erythrocyte deformability values obtained at all shear stress tested with the ektacytometer were
maintain unchanged and in an independent way of either the phosphorylated/dephosphorylated state of
the protein band 3 (Fig. 3) or the plasma ion level. To verify any RBC deformability change reper-
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cussions after the cdb3 phosphorylation/dephosphorylation it will be necessary to obtain either a de-
creasing /rupture in the number of membrane-skeleton bindings or absence of ankyrin as observed by
others [7].
In the present work the values of erythrocyte deformability are also maintained unchanged when the
inhibitors of the adenylyl cyclase (MDL), the guanylate cyclase (Ly) and the PI3K (Wort) are added to
the erythrocyte blood aliquots (Fig. 4) and as a net result no changes affected by oscillations in plasma
K+ levels were observed (slight significant increase values in relation to the control aliquot but without
physiological repercussions) (Fig. 6). In a similar way it may be admitted that these molecules stabilise
the erythrocyte membrane when compared with the blood sample aliquot control. Bor-Kucukatay et al.
[22] when utilise the selective inhibitor of the nitric oxide sensitive guanylate cyclase found a decrease
on the erythrocyte deformability which could add some insight to our results in a way that the absence
of RBC deformability changes obtained in presence of Ly may result either from an independent nitric
oxide influence or other complementary not yet described mechanism generated by the decrease cGMP
concentrations.
All together the inhibitors used in the present work do not interfere with any internal chain reactions
susceptibility to phosphorylate the spectrin proteins of the cytoskeleton that is known to decrease the
erythrocyte deformability [40].
At variance when either Ly or Wort were added, at fibrinogen concentration constant, the erythrocyte
aggregation values significantly decreased (Fig. 2) whereas stay unchanged in presence of the adenylyl
cyclase inhibitor, MDL. Others authors have verified a regulation of cyclic AMP phosphodiesterase ac-
tivity by PTK and PTP [9] which could explain the absence of a net effect on erythrocyte aggregation.
Concerning the action of Ly, a guanylate cyclase inhibitor, in RBC an increase of the MetHb concentra-
tion (Table 1) was obtained as a consequence of the absence of guanylate cyclase activation by NO. So
it will expect that more NO is available to react with the oxygenated haemoglobin molecules originating
MetHb and nitrites.
The inhibition of guanylate cyclase promotes a decrease in the cGMP concentration that could remove
its “internal cross-talk” with the cAMP specific phosphodiesterase removing the inhibition of the respec-
tive enzyme activity, as has been verified by others authors, conducting to the intracellular decrease of
the cAMP [30]. This could abolish the influence of the decrease of the cAMP concentration on EAI
values because these were unchanged in the presence of MDL. So the decrease of EAI values obtained
when Ly was added could occur by a signal transduction mechanism without the cAMP participation.
The significant p < 0.0001 decreased values of erythrocyte aggregation obtained in presence of Wort,
the PI3K inhibitor (Fig. 2), was not associated with an increase of plasma potassium ion concentration
which explanation need further studies such as testing the inhibitors utilised for different K+ membrane
transports systems [10]. It will need also to be verified if there is dependence from the increase of the
lactic fermentation rate as a consequence of the lack of pyruvate kinase phosphorylation PI3K depen-
dent [23].
In conclusion our results show that the erythrocyte aggregation tendency is higher when band 3 is
phosphorylated than when it’s partly desphosphorylated besides both band 3 states have lower EAI val-
ues in relation to the control blood values samples aliquots as a consequence of an in vitro manipulation
by PTK and PTP inhibitors.
Other proteins phosphorylation targets of GC and PI3K will not be excluded as contributing to lower
erythrocyte aggregation values.
It will be physiological relevant to test those inhibitors in blood samples with hyperviscosity syn-
dromes.
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